# of Displayed Technologies: 5 / 5

Applied Category Filter (Click To Remove): Infectious Diseases


Categories

Dynamic Nanobiosensor Platform for Viral and Tumor Nucleic Acid Detection
TS-052072 — A rapid, nucleic acid-based, point-of-care diagnostic.
The current gold-standard molecular diagnostic assay, quantitative reverse transcriptase (RT)-PCR, although accurate, is labor intensive (5-step workflow) and time consuming. Due to centralized laboratory testing, the time to results for RT-PCR can vary from 1 day up to 2 weeks, depending on the s…
  • College: College of Engineering (COE)
  • Inventors: Halley, Patrick; Castro, Carlos; Lucas, Christopher; Marras, Alexander; Shahhosseini, Melika
  • Licensing Officer: He, Panqing

A Novel Vaccine for Listeriosis Infection
TS-049471 — Listeriosis is an infectious disease caused by the bacterial pathogen Listeria monocytogenes. Although the average number of cases is moderate in the United States (1600-2500/year), listeriosis is a significant health concern due to its exceptionally high fatality rate. Indeed, listeriosis is the …
  • College: OSU Wexner Medical Center
  • Inventors: Seveau, Stephanie
  • Licensing Officer: He, Panqing

A novel STK1-targeted small molecule as an "antibiotic resistance breaker"
TS-037880 — Inh2-B1 serves as a therapeutically important “antibiotic-resistance-breaker,” which enhances the bactericidal activity of Ceftriaxone/Cefotaxime against highly pathogenic MDRSA infection.
Highly pathogenic and multidrug-resistant Staphylococcus species encompasses methicillin-resistant strains of S. aureus (MDRSA) and S. epidermidis (MDRSE) that have developed resistance to multiple traditional antibiotics, including the 5th generation cephalosporin (Ceftaroline). Because of the re…
  • College: College of Medicine (COM)
  • Inventors: Pancholi, Vijay
  • Licensing Officer: Davis, Stewart

A novel STK1-targeted small molecule as an "antibiotic resistance breaker"
TS-037880 — Inh2-B1 serves as a therapeutically important “antibiotic-resistance-breaker,” which enhances the bactericidal activity of Ceftriaxone/Cefotaxime against highly pathogenic MDRSA infection.
Highly pathogenic and multidrug-resistant Staphylococcus species encompasses methicillin-resistant strains of S. aureus (MDRSA) and S. epidermidis (MDRSE) that have developed resistance to multiple traditional antibiotics, including the 5th generation cephalosporin (Ceftaroline). Because of the re…
  • College: College of Medicine (COM)
  • Inventors: Pancholi, Vijay
  • Licensing Officer: Davis, Stewart

Novel bacterial Type II topoisomerase inhibitors for the treatment of bacterial infections
TS-037293 — Bacterial infections such as sexually transmitted diseases, meningitis, pneumonia, tuberculosis (TB), and tetanus are some of the most common infectious diseases. However, there are few drugs that can be used against all of these diseases, and several bacteria have developed resistance to many com…
  • College: College of Pharmacy
  • Inventors: Mitton-Fry, Mark
  • Licensing Officer: He, Panqing

Loading icon